Aurinia Pharmaceuticals Inc.
AUPH
$15.14
$0.231.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 265.81M | 260.11M | 247.30M | 235.13M | 220.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 265.81M | 260.11M | 247.30M | 235.13M | 220.36M |
| Cost of Revenue | 51.03M | 48.86M | 47.31M | 46.29M | 48.26M |
| Gross Profit | 214.78M | 211.25M | 199.99M | 188.84M | 172.11M |
| SG&A Expenses | 109.57M | 125.76M | 144.67M | 172.03M | 185.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 16.00M | 19.64M | 10.11M | 1.55M | 3.33M |
| Total Operating Expenses | 184.70M | 197.00M | 204.83M | 222.61M | 239.40M |
| Operating Income | 81.10M | 63.11M | 42.47M | 12.52M | -19.04M |
| Income Before Tax | 79.64M | 62.49M | 41.81M | 7.45M | -20.14M |
| Income Tax Expenses | 1.80M | 1.85M | 1.96M | 1.70M | 2.41M |
| Earnings from Continuing Operations | 77.84 | 60.64 | 39.85 | 5.75 | -22.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.84M | 60.64M | 39.85M | 5.75M | -22.55M |
| EBIT | 81.10M | 63.11M | 42.47M | 12.52M | -19.04M |
| EBITDA | 100.55M | 82.58M | 61.92M | 31.96M | 495.00K |
| EPS Basic | 0.58 | 0.44 | 0.28 | 0.04 | -0.16 |
| Normalized Basic EPS | 0.44 | 0.36 | 0.26 | 0.13 | -0.05 |
| EPS Diluted | 0.56 | 0.43 | 0.28 | 0.04 | -0.16 |
| Normalized Diluted EPS | 0.43 | 0.35 | 0.26 | 0.13 | -0.06 |
| Average Basic Shares Outstanding | 547.78M | 559.02M | 567.47M | 572.57M | 573.32M |
| Average Diluted Shares Outstanding | 564.41M | 574.05M | 580.64M | 581.45M | 576.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |